[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340570-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340570-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evolution-of-rapid-clonal-dynamics-and-noncross-resistance-in-response-to-alternating-targeted-therapy-and-chemotherapy-in-braf-v600e-mutant-colon-cancer","Evolution of Rapid Clonal Dynamics and Non–Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer","","Combined BRAF, MEK, and EGFR inhibition can produce responses in BRAF-V600E-mutant colorectal cancer, yet rapid resistance often limits durability. A pediatric case study uses serial circulating tumor DNA cfDNA profiling alongside patient-matched organoids from BRAF-V600E mutant mouse models to evaluate efficacy. Results link early resistance to MET amplification, followed by sequential chemotherapy plus targeted therapy clearing the resistant clone and enabling rechallenge response. Findings show monitoring-enabled, non–cross-resistant selection pressures and support rational sequential combination strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evolution-of-rapid-clonal-dynamics-and-noncross-resistance-in-response-to-alternating-targeted-therapy-and-chemotherapy-in-braf-v600e-mutant-colon-cancer/340570/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evolution-of-rapid-clonal-dynamics-and-noncross-resistance-in-response-to-alternating-targeted-therapy-and-chemotherapy-in-braf-v600e-mutant-colon-cancer/340570.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of combining BRAF, MEK, and EGFR inhibition in BRAF-V600E-mutant colon cancer?","Question",{"text":63,"@type":64},"To induce clinical responses despite the frequent emergence of rapid resistance, by understanding how treatment regimens influence drug sensitivity and resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were resistance and treatment response monitored in the study?",{"text":68,"@type":64},"Through serial circulating tumor DNA analysis from cell-free plasma DNA, complemented by organoids derived from BRAF-V600E-mutant mouse models to recapitulate the patient’s mutational profile.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism was associated with initial resistance, and what happened after sequential therapy?",{"text":72,"@type":64},"Initial resistance to targeted therapy was associated with development of MET amplification; sequential chemotherapy and targeted therapy cleared the MET-amplified resistant clone and enabled response on rechallenge.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340570,1790470173,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Original Reports | Cancer Genetics  \nEvolution of Rapid Clonal Dynamics and Non– Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer  \nSrilatha Simhadri, PhD1; Jillian N. Carrick, BA2,3 ; Susan Murphy, PhD4 ; Om A. Kothari, BS2; Husam Al-Hraishami, PhD1; Atul Kulkarni, PhD1; Nahed Jalloul, PhD5 ; Katarina Stefanik, BS2,6 ; Manisha Bandari, BS3; Kavya Chettur3,7 ; Ming Yao, PhD1; Vasudeva Ginjala, PhD1 ; Roman Groisberg, MD1 ; Howard Hochster, MD1 ; Janice Mehnert, MD1 ; Gregory Riedlinger, MD, PhD5 ; Hossein Khiabanian, PhD5 ; Michael P. Verzi, PhD2; Kevin Tong, PhD2,6,8 ; and Shridar Ganesan, MD, PhD1   \nDOI [https://doi.org/10.1200/PO.23.00260](https://doi.org/10.1200/PO.23.00260)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Combined BRAF, MEK, and EGFR inhibition can induce clinical responses in BRAF-V600E-mutant colon cancer, but rapid resistance often occurs. |\n| METHODS | We use serial monitoring of circulating tumor DNA cell-free plasma DNA (cfDNA) in a patient case study in addition to organoids derived from mouse models of BRAF-V600E-mutant intestinal cancer, which emulated the patient’s mutational proﬁle to assess drug treatment efﬁcacy. |\n| RESULTS | We demonstrate dynamic evolution of resistance to combined EGFR/BRAF/MEK inhibition in a pediatric patient with metastatic BRAF-V600E-mutant, mismatch repair-stable colon cancer. Initial resistance to targeted therapy was associated with development of MET ampliﬁcation. Sequential treatment with chemotherapy and targeted therapy resulted in clearing of the resistant METampliﬁed clone. Rechallenge with combined BRAF/EGFR inhibition resulted in clinical and radiographic response, demonstrating these treatments may be non–cross-resistant. Tumor organoidswere used to model clinical ﬁndings and demonstrated effectiveness of combined targeted therapy and chemotherapy. |\n| CONCLUSION | These ﬁndings suggest rational strategies for combining sequential chemotherapy and BRAF-/EGFR-directed therapy in BRAF-V600E-mutant colon cancer to prevent resistance and improve outcome. The data demonstrate rapid clonal dynamics in response to effective therapies in BRAF-V600E-mutant colon cancer that can be monitored by serial cfDNA analysis. Moreover, in mismatch repair-proﬁcient BRAF-V600E-mutant colon cancers, combined EGFR and BRAF/MEK therapy is not cross-resistant with standard chemotherapy, suggesting new rational combination treatment strategies. |\n\nACCOMPANYING CONTENT  \n Appendix  \nAccepted September 27, 2024 Published December 3, 2024  \nJCO Precis Oncol 8:e2300260 © 2024 by American Society of Clinical Oncology  \nLicensed under the Creative  \nCommons Attribution 4.0 License  \nINTRODUCTION  \nApproximately 8%-15% of colorectal cancers (CRC) harbor a BRAF-V600E mutation, which is associated with aggressive disease, poor prognosis, and does not show signiﬁcant response to standard therapy nor BRAF/MEK inhibitors.1-7 A subset of metastatic BRAF-V600E-mutant colon cancers also show evidence of microsatellite instability and defective mismatch repair because of hMLH1 promoter hypermethylation and the CpG island methylator phenotype.1 ,2 Likely because of adaptive activation of EGFR signaling in the setting of mitogen-activated protein kinase pathway inhibition, BRAF-V600E-mutant colon cancers generally do not beneﬁt from addition of anti-EGFR antibody to standard  \nchemotherapy.1,2 However, a phase III trial demonstrating that a doublet of BRAF inhibitor with an EGFR antibody, and triplet of BRAF, MEK, and EGFR inhibitors, resulted in signiﬁcantly longer overall survival and higher response rate than standard chemotherapy in patients with BRAF-V600E metastatic colorectal cancer.8 However, these responses are often short-lived and acquired resistance develops through multiple mechanisms.9 Thus, there is a pressing need to develop novel strategies to improve the durability of treatment responses and target resistance mechanisms.  ","cbCaikbL7vl49SXK","https://ap.wps.com/l/cbCaikbL7vl49SXK","pdf",3406660,12,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance\n# Methods\n## Patient Case Study","[{\"question\":\"What was the main purpose of combining BRAF, MEK, and EGFR inhibition in BRAF-V600E-mutant colon cancer?\",\"answer\":\"To induce clinical responses despite the frequent emergence of rapid resistance, by understanding how treatment regimens influence drug sensitivity and resistance.\"},{\"question\":\"How were resistance and treatment response monitored in the study?\",\"answer\":\"Through serial circulating tumor DNA analysis from cell-free plasma DNA, complemented by organoids derived from BRAF-V600E-mutant mouse models to recapitulate the patient’s mutational profile.\"},{\"question\":\"What mechanism was associated with initial resistance, and what happened after sequential therapy?\",\"answer\":\"Initial resistance to targeted therapy was associated with development of MET amplification; sequential chemotherapy and targeted therapy cleared the MET-amplified resistant clone and enabled response on rechallenge.\"}]","Evolution of Rapid Clonal Dynamics and Non–Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer | PDF",1790037452,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a31441023d4255fe9e4696b204103ff5.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd7a58e32c7bc8e872c00fb927e22cff.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d49cf50ce9aab8c493aaa48673f4af20.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/836b2980529c1984ab416c8f55af06ea.webp",980,1311]